Radius Health (RDUS) PT Raised to $45 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Radius Health (RDUS) PT Raised to $52 at Cantor Fitzgerald
December 23, 2014 8:19 AM ESTCantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating and boosted her price target on Radius Health (NASDAQ: RDUS) to $52.00 (from $26.00) following positive phase 3 trials of Abaloparatide-SC.
"With the first hurdle (18-month data) achieved, we believe that abaloparatide-SC is significantly de-risked,... More
Radius Health (RDUS) Reports Positive Top-Line Abaloparatide-SC Phase 3 Data
December 22, 2014 6:42 AM ESTRadius Health (Nasdaq: RDUS) announced positive top-line 18-month fracture results from the Company's Phase 3 clinical trial (ACTIVE) evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis.
On the primary endpoint, the investigational drug abaloparatide-SC (n=690, fracture rate 0.72%) achieved a statistically significant 83% reduction of incident vertebral fractures as compared to the placebo-treated group (n=711, fracture rate 4.36%)... More
